Cartesian Therapeutics, Inc.
RNAC
Rang in Aktien
#18194
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Aktienkurs
$6.44
Marktkapitalisierung
$194.84M
Veränderung (1 Tag)
0.70%
Veränderung (1 Jahr)
865.08%
Land
US
Handel Cartesian Therapeutics, Inc. (RNAC)
Kategorie
Healthcare
Kursverlauf für Cartesian Therapeutics, Inc. (RNAC)
Höchster Schlusskurs: $0.79 am 2023-12-01
Niedrigster Schlusskurs: $14.00 am 2016-06-01
Niedrigster Schlusskurs: $14.00 am 2016-06-01
Kursverlauf der Aktie von Cartesian Therapeutics, Inc. von 2016 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2023 | -33.64% |
| 2022 | -62.77% |
| 2021 | 0.01% |
| 2020 | 73.71% |
| 2019 | -58.81% |
| 2018 | -55.20% |
| 2017 | -51.08% |
| 2016 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
